Oramed receives warrant to buy 100k Scilex shares at $20 in exchange for deferring amortization payment

ORAMED PHARMACEUTICALS INC.

Oramed deferred its right to receive an amortization payment from Scilex due Oct 1, 2025; payment was made in Nov 2025.
Oramed received a warrant to purchase 100,000 shares of Scilex common stock at $20.00 per share, expiring Dec 13, 2029.
Warrant issued under Section 4(a)(2) and Rule 506(b); Scilex agreed to file resale registration statement.
Beneficial ownership limited to 4.99% (can be raised to 9.99% with 61 days' notice).
Warrant immediately exercisable; exercise price subject to anti-dilution adjustments with floor of $8.22.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ORAMED PHARMACEUTICALS INC. entered into Warrant Agreement with Scilex Holding Company (effective 2026-02-19).

Action: entry
Counterparty: Scilex Holding Company
Effective: 2026-02-19

Exact text from the filing

On February 19, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into a Warrant Agreement (the “Warrant Agreement”) with Scilex Holding Company (“Scilex”).

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

ORAMED PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001012975-26-000195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.